ArticleJournal of medical biochemistry2025
Changes in serum cholyglycine and prealbumin levels, glutamyl transpeptidase, and Alpha-fetoprotein after transcatheter arterial chemoembolisation combined with microwave ablation of liver cancer.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the clinical outcomes of transcatheter arterial chemoembolisation (TACE) alone and in combination with microwave ablation (MWA) for patients with middle- or advanced-stage primary liver cancer (PLC) and analyse the causes of complications. Methods: A total of 100 patients with middle or advancedstage PLC were divided into two groups: the TACE group (TACEG, n = 50), which received TACE alone, and the combination group (CG, n = 50), which underwent TACE combined with MWA. Clinical parameters were evaluated before and after treatment, including the quality of life (QoL) assessed by the SF-36 score, serum liver function indices, treatment response, 1-year overall survival (OS) rate, and complication rates. Results: Compared to the TACEG, the CG demonstrated significantly higher SF-36 scores, objective response rate (ORR) (32% vs 50%), disease control rate (Dc R) (82% vs 90%), and 1-year OS (60% vs 84%), while exhibiting a lower 1-year complication rate (34% vs 16%). Additionally, post-treatment levels of cholyglycine (CG) and prealbumin (PAB) were significantly higher in the CG, whereas total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and alpha-fetoprotein (AFP) were significantly lower (all P< 0.05). Conclusions: TACE combined with MWA is an effective and safe treatment for middle or advanced PLC, significantly improving liver function and postoperative survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.